Skip to content

Study · Non-randomized trial · n = 80 · 2024

5 results

Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration.

Kuerec AH, Wang W, Yi L, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V, Maier AB

Mechanisms of ageing and development29 Feb 2024Cited by 13 (Europe PMC)

PMID38430946 (opens in a new tab)DOI10.1016/j.mad.2024.111917 (opens in a new tab)PepBankPUB-38430946
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

Nicotinamide mononucleotide (NMN) is a precursor of nicotinamide adenine dinucleotide (NAD), which declines with age. Supplementation of NMN has been shown to improve blood NAD concentration. However, the optimal NMN dose remains unclear. This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40-65 years. The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days. Blood NAD concentration, blood biological age, homeostatic model assessment for insulin resistance, 6-minute walk test, and 36-item short-form survey (SF-36) were measured at baseline and after supplement. A significant dose-dependent increase in NAD concentration change (NADΔ) was observed following NMN supplementation, with a large coefficient of variation (29.2-113.3%) within group. The increase in NADΔ was associated with an improvement in the walking distance of 6-minute walk test and the SF-36 score. The median effect dose of NADΔ for the 6-minute walk test and SF-36 score was 15.7 nmol/L (95% CI: 10.9-20.5 nmol/L) and 13.5 nmol/L (95% CI; 10.5-16.5 nmol/L), respectively. Because of the high interindividual variability of the NADΔ after NMN supplementation, monitoring NAD concentration can provide valuable insights for tailoring personalized dosage regimens and optimizing NMN utilization.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In generally healthy adults, NMN increased blood NAD concentration in a dose-dependent manner, with substantial within-group variability.

    In plain wordsNMN increased blood NAD levels in generally healthy adults, with large differences between individuals.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseBlood NAD concentration change
    Study

    n = 80

    Outcome group
    Pharmacokinetics · Metabolic and weight
    Studied dose
    300, 600, or 900 mg daily · 60 daysAs given in this study (human).

    Measurements

    Coefficient of variation
    29.2 to 113.3%
    within group

    Source sentences

    Summary
    A significant dose-dependent increase in NAD concentration change (NADΔ) was observed following NMN supplementation, with a large coefficient of variation (29.2-113.3%) within group.
    2 context sentences
    Summary · context
    This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40-65 years.
    Summary · context
    The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days.
  2. 02HumanNon-randomized trialMechanism

    In adults receiving NMN, greater NAD increases were associated with improved walking distance.

    In plain wordsIn adults receiving NMN, greater NAD increases were linked to longer walking distances.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseWalking distance association with NAD change
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    300, 600, or 900 mg daily · 60 daysAs given in this study (human).

    Source sentences

    Summary
    The increase in NADΔ was associated with an improvement in the walking distance of 6-minute walk test and the SF-36 score.
    2 context sentences
    Summary · context
    This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40-65 years.
    Summary · context
    The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days.
  3. 03HumanNon-randomized trialMechanism

    In adults receiving NMN, greater NAD increases were associated with improved SF-36 scores.

    In plain wordsIn adults receiving NMN, greater NAD increases were linked to better SF-36 scores.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseSF-36 association with NAD change
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    300, 600, or 900 mg daily · 60 daysAs given in this study (human).

    Source sentences

    Summary
    The increase in NADΔ was associated with an improvement in the walking distance of 6-minute walk test and the SF-36 score.
    2 context sentences
    Summary · context
    This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40-65 years.
    Summary · context
    The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days.
  4. 04HumanNon-randomized trialMechanism

    In adults, the median NAD change associated with the walking test effect was 15.7 nmol/L.

    In plain wordsThe median NAD change for the walking test effect was 15.7 nmol/L in adults.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicableMedian NAD effect dose for walking distance
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    300, 600, or 900 mg daily · 60 daysAs given in this study (human).

    Measurements

    Median effect dose
    15.7 nmol/L
    6-minute walk test
    95% CI
    10.9 to 20.5 nmol/L
    6-minute walk test

    Source sentences

    Summary
    The median effect dose of NADΔ for the 6-minute walk test and SF-36 score was 15.7 nmol/L (95% CI: 10.9-20.5 nmol/L) and 13.5 nmol/L (95% CI; 10.5-16.5 nmol/L), respectively.
    2 context sentences
    Summary · context
    This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40-65 years.
    Summary · context
    The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days.
  5. 05HumanNon-randomized trialMechanism

    In adults, the median NAD change associated with the SF-36 effect was 13.5 nmol/L.

    In plain wordsThe median NAD change for the SF-36 effect was 13.5 nmol/L in adults.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicableMedian NAD effect dose for SF-36
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    300, 600, or 900 mg daily · 60 daysAs given in this study (human).

    Measurements

    Median effect dose
    13.5 nmol/L
    SF-36
    95% CI
    10.5 to 16.5 nmol/L
    SF-36

    Source sentences

    Summary
    The median effect dose of NADΔ for the 6-minute walk test and SF-36 score was 15.7 nmol/L (95% CI: 10.9-20.5 nmol/L) and 13.5 nmol/L (95% CI; 10.5-16.5 nmol/L), respectively.
    2 context sentences
    Summary · context
    This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40-65 years.
    Summary · context
    The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.